Sanofi: FDA lifts clinical hold on fitusiran
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
BofA/Merrill Lynch Remains Sidelined on Sanofi (SNY) Following R&D Meeting
December 18, 2017 9:20 AM ESTBofA/Merrill Lynch reiterates a Neutral rating and $49.00 price target on Sanofi (NYSE: SNY) following the company's R&D Q&A session.
Although Sanofi suggested its PIII lung program for cemiplimab has PFS as a primary endpoint, it clarified today that the... More
